Global Atrial Fibrillation Market 2015-2019

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Product Profiles
04.1.1 Pradaxa/ Prazaxa
04.1.2 Xarelto
04.1.3 Multaq
05. Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology
06. Introduction
07. Disease Overview
07.1 Understanding the Disease
07.2 Classification
07.3 Pathophysiology
07.4 Causes
07.5 Epidemiology
07.6 Management
07.7 Economic Burden
08. Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis
09. Market Segmentation by Class of Drugs
09.1.1 Anticoagulants
09.1.2 Anti-arrythmics
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 Boehringer Ingelheim
18.2.2 Sanofi
18.2.3 Janssen Pharmaceuticals
18.3 Other Prominent Vendors
19. Key Vendor Analysis
19.1 Boehringer Ingelheim
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Business Segmentation by Revenue 2013
19.1.4 Business Segmentation by Revenue 2012 and 2013
19.1.5 Geographical Segmentation by Revenue 2013
19.1.6 Business Strategy
19.1.7 Recent Developments
19.1.8 SWOT Analysis
19.2 Janssen Pharmaceuticals
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Recent Developments
19.2.4 SWOT Analysis
19.3 Sanofi
19.3.1 Key Facts
19.3.2 Business Description
19.3.3 Business Segmentation
19.3.4 Revenue by Business Segmentation
19.3.5 Revenue Comparison 2012 and 2013
19.3.6 Sales by Geography
19.3.7 Business Strategy
19.3.8 Key Developments
19.3.9 SWOT Analysis
20. Other Reports in this Series